Compare Amcor PLC (AMCR) vs Cigna Corp (CI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amcor PLC vs Cigna Corp — how do they compare? Amcor PLC trades at $42.75 (market cap $19.96B), while Cigna Corp trades at $302.46 (market cap $77.63B). The key difference: Cigna Corp is far larger — about 3.9× Amcor PLC's market cap, and Amcor PLC pays the higher dividend (6.02%). Which is the better fit depends on your goals.
| AMCR | CI | |
|---|---|---|
Market Cap | $19.96B | $77.63B |
Sector | Basic Materials | Health |
52-Week High | $50.58 | $311.00 |
52-Week Low | $36.69 | $244.41 |
Enterprise Value | $35.08B | $100.73B |
Dividend Yield | 6.02% | 2.13% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMCR trades at $43.18, up 1.12% today, with a bullish technical outlook and strong analyst consensus. The stock shows consistent earnings beats in recent quarters, with Q2 2026 EPS expected at $1.19. Revenue grew to $15.01B in 2025, though net income margin declined to 3.06%. Recent news highlights expansion in China and sustainable packaging partnerships, supporting growth prospects amid investor optimism.
The outlook for AMCR is positive, driven by earnings momentum and strategic initiatives, but risks include margin pressure and integration challenges from the Berry acquisition. With a consensus price target of $45.75, upside potential exists, though investors should monitor debt levels and competitive pressures in the packaging sector.
Cigna (CI) trades at $293.46, up 0.57% on the day, with a bullish technical signal and strong analyst support. The stock shows consistent earnings beats, with Q1 2026 EPS of $7.79 exceeding the $7.60 estimate. Valuation metrics appear attractive with a P/E of 12.44 and P/S of 0.28. Recent news highlights strategic initiatives, including AI integration in pharmacy services. The current price is near the consensus price target of $339.82, indicating potential upside.
The outlook for CI is positive, driven by earnings momentum, a favorable analyst consensus, and strategic growth investments. Key risks include regulatory challenges, as seen in a recent lawsuit in Tennessee, and competitive pressures in the healthcare sector. Net cash flow turned negative in 2025, which warrants monitoring. The stock presents a value opportunity with a solid dividend, but investors should weigh execution risks against growth potential.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amcor PLC
Amcor is a global plastics packaging behemoth, with global sales of USD 14.5 billion in fiscal 2022 following the acquisition of Bemis in 2019. Amcor's operations span over 40 countries globally and include significant emerging-market exposure equating to circa 20% of sales. Amcor's capabilities span flexible and rigid plastic packaging, which sell into defensive food, beverage, healthcare, household, and personal-care end markets.
Read more on AMCR →About Cigna Corp
Cigna primarily provides pharmacy benefit management and health insurance services. Its PBM services were greatly expanded by its 2018 merger with Express Scripts and are mostly sold to health insurance plans and employers. Its largest PBM contract is the Department of Defense. In health insurance and other benefits, Cigna mostly serves employers through self-funding arrangements, but it also operates in government programs, such as Medicare Advantage. The company operates mostly in the U.S. with 15 million medical members covered as of the end of 2020, but its services extend internationally, covering another 2 million people.
Read more on CI →
